실적분석 2026년 8월 11일

Legend Biotech ($LEGN) Q2 2026 Earnings Analysis — Revenue Beat, Swing to Profit, but Adjusted EPS Misses Estimates

Earnings Scorecard

Revenue: $387.5M (+51.9% YoY, vs. $352M estimate) ✅ Beat

EPS: Adjusted basic $0.17 / diluted $0.16 (vs. $0.28 estimate, adjusted basis) ❌ Miss · IFRS basic and diluted $0.09 each

Guidance: Not provided — no specific revenue or EPS outlook. Reaffirmed commitment to achieving full-year 2026 GAAP profitability (adjusted net income basis) and reaffirmed liquidity capacity beyond 2026

Stock Reaction: +6.49% after-hours ($22) — as of 08-11, 20:53 KST

The Positives

Revenue Surprise: Total revenue of $387.5M exceeded the $352M consensus estimate.

Quarterly Swing to Profit: Net income of $33.2M (Q2 2026) marked a turnaround from a loss in the prior-year period.

CARVYKTI Growth: Net trade sales of approximately $657M, up 50% YoY.

Continued U.S. and international penetration of lead product CARVYKTI drove simultaneous growth in collaboration revenue and Janssen milestone payments. Operating income also flipped to a $57.7M profit from a prior-year loss, signaling improving underlying business profitability.

The Negatives

Adjusted EPS Shortfall: Adjusted basic EPS of $0.17 fell well short of the $0.28 estimate.

Sharp Tax Expense Increase: Income tax expense of $22.3M (vs. $0.6M prior year) weighed on earnings.

Leadership Transition: Interim CEO structure leaves uncertainty around strategic continuity.

Adjusted earnings improved, but did not deliver the per-share profit strength the market expected. With advance pricing agreement negotiations ongoing with Chinese tax authorities, the final tax amount remains subject to change, and maintaining execution discipline during the CEO transition is a key consideration.

What Management Said

Interim CEO Alan Bash emphasized that CARVYKTI's growth alongside in vivo CAR-T platform validation demonstrates commercial and innovation engines operating in tandem. While specific revenue and EPS guidance was withheld, he expressed confidence in the trajectory toward 2026 full-year GAAP profitability and a strengthened liquidity position — which the market appears to have read as a "directional reaffirmation in the absence of hard numbers."

Market Reaction and Key Points Ahead

Despite the adjusted EPS miss, the revenue beat, quarterly return to profitability, CARVYKTI growth, pipeline progress, and cash position bolstered by the equity offering appear to have offset disappointment and driven the after-hours rally.

Watch whether CARVYKTI net trade sales growth and the international revenue mix hold up in Q3.

Monitor how tax expense and transfer-pricing estimates translate into actual cash taxes.

Keep an eye on the appointment of a permanent CEO and any updates to the path toward 2026 full-year GAAP profitability (adjusted net income).